CELU

Company Overview — What Does Celularity Inc Do?

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase 1 clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase 1 clinical trial to treat acute myeloid leukemia, as well as in Phase 1/2a clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase 1 clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey. Celularity Inc (CELU) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Robert Joseph Hariri Gordon and employs approximately 220 people. With a market capitalization of $38M, CELU is one of the notable companies in the Healthcare sector.

Celularity Inc (CELU) Stock Rating — Reduce (April 2026)

As of April 2026, Celularity Inc receives a Reduce rating with a composite score of 23.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CELU ranks #3,662 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Celularity Inc ranks #599 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CELU Stock Price and 52-Week Range

Celularity Inc (CELU) currently trades at $1.29. The stock lost $0.07 (5.1%) in the most recent trading session. The 52-week high for CELU is $4.35, which means the stock is currently trading -70.3% from its annual peak. The 52-week low is $1.01, putting the stock 27.7% above its annual trough. Recent trading volume was 12K shares, suggesting relatively thin trading activity.

Is CELU Overvalued or Undervalued? — Valuation Analysis

Celularity Inc (CELU) carries a value factor score of 15/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 1.26x, compared to 1.66x for the average Healthcare stock.

At current multiples, Celularity Inc trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Celularity Inc Profitability — ROE, Margins, and Quality Score

Celularity Inc (CELU) earns a quality factor score of 12/100, signaling below-average profitability metrics relative to the broader market. Return on assets (ROA) comes in at -73.0% versus the sector average of -33.1%.

On a margin basis, Celularity Inc reports gross margins of 40.5%, compared to 71.5% for the sector. The operating margin is -184.1% (sector: -66.1%). Net profit margin stands at -302.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -56.4% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CELU Debt, Balance Sheet, and Financial Health

Balance sheet data for CELU is evaluated through our stability factor. The current ratio is 0.16x, which may signal near-term liquidity tightness.

CELU has a beta of 1.25, meaning it is more volatile than the broader market — a $10,000 investment in CELU would be expected to move 25.0% more than the S&P 500 on any given day. The stability factor score for Celularity Inc is 21/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Celularity Inc Revenue and Earnings History — Quarterly Trend

In TTM 2026, Celularity Inc reported revenue of $32M and earnings per share (EPS) of $-0.88. Net income for the quarter was $-83M. Gross margin was 40.5%. Operating income came in at $-51M.

In Q3 2025, Celularity Inc reported revenue of $5M and earnings per share (EPS) of $-0.88. Net income for the quarter was $-23M. Gross margin was 26.1%. Revenue grew -43.2% year-over-year compared to Q3 2024. Operating income came in at $-13M.

In Q2 2025, Celularity Inc reported revenue of $6M and earnings per share (EPS) of $-1.02. Net income for the quarter was $-25M. Gross margin was 8.6%. Revenue grew -52.6% year-over-year compared to Q2 2024. Operating income came in at $-16M.

In Q1 2025, Celularity Inc reported revenue of $11M and earnings per share (EPS) of $-0.84. Net income for the quarter was $-20M. Gross margin was 68.9%. Revenue grew -22.2% year-over-year compared to Q1 2024. Operating income came in at $-10M.

Over the past 8 quarters, Celularity Inc has demonstrated a growth trajectory, with revenue expanding from $15M to $32M. Investors analyzing CELU stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CELU Dividend Yield and Income Analysis

Celularity Inc (CELU) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CELU Momentum and Technical Analysis Profile

Celularity Inc (CELU) has a momentum factor score of 24/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 52/100 reflects moderate short selling activity.

CELU vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Celularity Inc (CELU) ranks #599 out of 838 stocks based on the Blank Capital composite score. This places CELU in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CELU against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CELU vs S&P 500 (SPY) comparison to assess how Celularity Inc stacks up against the broader market across all factor dimensions.

CELU Next Earnings Date

No upcoming earnings date has been announced for Celularity Inc (CELU) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CELU? — Investment Thesis Summary

The quantitative profile for Celularity Inc suggests caution. The quality score of 12/100 flags below-average profitability. The value score of 15/100 indicates premium valuation. Momentum is weak at 24/100, a headwind for near-term performance. High volatility (stability score 21/100) increases portfolio risk.

In summary, Celularity Inc (CELU) earns a Reduce rating with a composite score of 23.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CELU stock.

Related Resources for CELU Investors

Explore more research and tools: CELU vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CELU head-to-head with peers: CELU vs AZN, CELU vs SLGL, CELU vs VMD.